Wordt geladen...
Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience
BACKGROUND: Metastatic uveal melanoma (MUM) is associated with a poor prognosis, with a median overall survival (OS) of 4–15 months. Despite new insights into the genetic and molecular background of MUM, satisfactory systemic treatment approaches are currently lacking. The study results of innovativ...
Bewaard in:
| Gepubliceerd in: | Case Rep Oncol Med |
|---|---|
| Hoofdauteurs: | , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Hindawi
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6501230/ https://ncbi.nlm.nih.gov/pubmed/31179139 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2019/3560640 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|